"We continue to see the Impower 150 study in lung cancer decisive for Tecentriq and Roche's top-line growth," said Bruno Bulic, a Baader Helvea analyst. ($1 = 0.9801 Swiss francs) (Reporting by John Miller; Editing by Michael Shields and David Holmes)